These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37992360)

  • 1. Immunotherapy and Its Timing in Advanced Basal Cell Carcinoma Treatment.
    Dessinioti C; Stratigos AJ
    Dermatol Pract Concept; 2023 Oct; 13(4):. PubMed ID: 37992360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
    Stratigos AJ; Sekulic A; Peris K; Bechter O; Prey S; Kaatz M; Lewis KD; Basset-Seguin N; Chang ALS; Dalle S; Orland AF; Licitra L; Robert C; Ulrich C; Hauschild A; Migden MR; Dummer R; Li S; Yoo SY; Mohan K; Coates E; Jankovic V; Fiaschi N; Okoye E; Bassukas ID; Loquai C; De Giorgi V; Eroglu Z; Gutzmer R; Ulrich J; Puig S; Seebach F; Thurston G; Weinreich DM; Yancopoulos GD; Lowy I; Bowler T; Fury MG
    Lancet Oncol; 2021 Jun; 22(6):848-857. PubMed ID: 34000246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness.
    Mannino M; Piccerillo A; Fabbrocini G; Quaglino P; Argenziano G; Dika E; Ascierto PA; Pellacani G; Longo C; Fargnoli MC; Bianchi L; Calzavara-Pinton P; Zalaudek I; Fava P; Scalvenzi M; Bocchino E; Di Stefani A; Peris K;
    Dermatology; 2023; 239(6):868-876. PubMed ID: 37311439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma.
    Doan HQ; Chen L; Nawas Z; Lee HH; Silapunt S; Migden M
    Oncotarget; 2021 Sep; 12(20):2089-2100. PubMed ID: 34611482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supraorbital Basosquamous Carcinoma Treated with Cemiplimab Followed by Sonidegib: A Case Report and Review of the Literature.
    Proietti I; Filippi L; Tolino E; Bernardini N; Svara F; Trovato F; Di Cristofano C; Petrozza V; Bagni O; Vizzaccaro A; Skroza N; Potenza C
    Biomedicines; 2023 Oct; 11(11):. PubMed ID: 38001904
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of Hedgehog pathway inhibitors used in the treatment of advanced or treatment-refractory basal cell carcinoma.
    Lear JT; Morris LM; Ness DB; Lewis LD
    Expert Rev Clin Pharmacol; 2023; 16(12):1211-1220. PubMed ID: 37975712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Targeted Treatments for Basal Cell Carcinoma.
    Svoboda SA; Johnson NM; Phillips MA
    Cutis; 2022 Jun; 109(6):E25-E31. PubMed ID: 35960978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma.
    Lear JT; Dummer R; Guminski A
    Oncotarget; 2021 Dec; 12(26):2531-2540. PubMed ID: 34966484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
    Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
    J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports.
    Colombo E; Gurizzan C; Ottini A; Caspani F; Bergamini C; Locati LD; Marchiselli C; Alberti A; Lorini L; Licitra LF; Bossi P; Resteghini C
    Front Oncol; 2023; 13():1111146. PubMed ID: 36925925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023.
    Peris K; Fargnoli MC; Kaufmann R; Arenberger P; Bastholt L; Seguin NB; Bataille V; Brochez L; Del Marmol V; Dummer R; Forsea AM; Gaudy-Marqueste C; Harwood CA; Hauschild A; Höller C; Kandolf L; Kellerners-Smeets NWJ; Lallas A; Leiter U; Malvehy J; Marinović B; Mijuskovic Z; Moreno-Ramirez D; Nagore E; Nathan P; Stratigos AJ; Stockfleth E; Tagliaferri L; Trakatelli M; Vieira R; Zalaudek I; Garbe C;
    Eur J Cancer; 2023 Oct; 192():113254. PubMed ID: 37604067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Treatment Patterns and Outcomes Among Patients with Basal Cell Carcinoma Following First-Line Hedgehog Inhibitor Discontinuation.
    Cowey L; Chen CI; Aguilar KM; Davies K; LaFontaine PR; Fury MG; Bowler T; Golozar A; Jalbert JJ
    Dermatol Ther (Heidelb); 2022 May; 12(5):1211-1224. PubMed ID: 35507216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current clinical approach to difficult-to-treat basal cell carcinomas.
    Di Brizzi EV; Argenziano G; Brancaccio G; Scharf C; Ronchi A; Moscarella E
    Expert Rev Anticancer Ther; 2023 Jan; 23(1):43-56. PubMed ID: 36579630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion.
    Dummer R; Ascierto PA; Basset-Seguin N; Dréno B; Garbe C; Gutzmer R; Hauschild A; Krattinger R; Lear JT; Malvehy J; Schadendorf D; Grob JJ
    J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):1944-1956. PubMed ID: 31990414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hedgehog Pathway Inhibitors: Clinical Implications and Resistance in the Treatment of Basal Cell Carcinoma.
    Habashy S; Jafri A; Osman HO; Thomas NE; Udekwe S; Heindl SE
    Cureus; 2021 Mar; 13(3):e13859. PubMed ID: 33754119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
    Lacouture ME; Dréno B; Ascierto PA; Dummer R; Basset-Seguin N; Fife K; Ernst S; Licitra L; Neves RI; Peris K; Puig S; Sokolof J; Sekulic A; Hauschild A; Kunstfeld R
    Oncologist; 2016 Oct; 21(10):1218-1229. PubMed ID: 27511905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis.
    Ge W; Chen CI; Wu N; Fury MG; Ruiz E; Jalbert JJ
    Future Oncol; 2022 Jul; 18(23):2561-2572. PubMed ID: 35735026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Not Available].
    Basset-Seguin N
    Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
    Leavitt E; Lask G; Martin S
    Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Approaches in Non-Melanoma Skin Cancers-A Focus on Hedgehog Pathway in Basal Cell Carcinoma (BCC).
    Chmiel P; Kłosińska M; Forma A; Pelc Z; Gęca K; Skórzewska M
    Cells; 2022 Oct; 11(20):. PubMed ID: 36291078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.